ArticleNature2021
Author Correction: IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cells.
Open access · bronzeAbstract readPublished Erratum
In one paragraph
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 62% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
- Erratum for
Authors and funding
29 authors at 10 institutions in 2 countries.
Jaewoong LeeCenter of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Mark E RobinsonCenter of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0003-2363-6047
Ning MaDepartment of Computational and Quantitative Medicine, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Dewan ArtadjiCenter of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0002-1189-6936
Mohamed A AhmedDepartment of Systems Biology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0003-4476-0768
Gang XiaoDepartment of Systems Biology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Teresa SadrasCenter of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Gauri DebDepartment of Systems Biology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Janet WinchesterDepartment of Systems Biology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Kadriye Nehir CosgunCenter of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Huimin GengDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
Lai N ChanCenter of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Kohei KumeCenter of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0003-2856-5970
Teemu P MiettinenKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-5975-200X
Ye ZhangKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Matthew A NixDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-7741-5368
Lars KlemmCenter of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Chun Wei ChenDepartment of Systems Biology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0002-8737-6830
Jianjun ChenDepartment of Systems Biology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0003-3749-2902
Vishal KhairnarDepartment of Systems Biology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Arun P WiitaDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-7465-6964
Andrei Thomas-TikhonenkoDepartment of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Michael FarzanDepartment of Immunology and Microbiology, The Scripps Research Institute, Jupiter, FL, USA.ORCID http://orcid.org/0000-0002-2990-5319
Jae U JungDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0003-4559-8774
David M WeinstockDana Farber Cancer Institute, Boston, MA, USA.
Scott R ManalisKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-5223-9433
Michael S DiamondDepartment of Medicine, Washington University School of Medicine in St Louis, St Louis, MO, USA.ORCID http://orcid.org/0000-0002-8791-3165
Nagarajan VaidehiDepartment of Computational and Quantitative Medicine, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0001-8100-8132
Markus MüschenCenter of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA. markus.muschen@yale.edu.ORCID http://orcid.org/0000-0002-6064-8613
City of Hope · USYale Cancer Center · USUniversity of California, San Francisco · USMassachusetts Institute of Technology · USChildren's Hospital of Philadelphia · USCleveland Clinic Lerner College of Medicine · USHarvard University · USMRC Laboratory for Molecular Cell Biology · GBScripps Research Institute · USWashington University in St. Louis · US
Funding
Targeting FTO to treat acute myeloid leukemiaR01CA243386 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, JIANJUN · 2020 to 2024
$2.8MTargeting TET1 signaling to treat acute myeloid leukemiaR01CA211614 · NCI · UNIVERSITY OF CINCINNATI · PI CHEN, JIANJUN · 2017 to 2021
$2.3MThe role and mechanism of FTO in leukemogenesis and drug responseR01CA214965 · NCI · UNIVERSITY OF CINCINNATI · PI CHEN, JIANJUN · 2017 to 2021
$2.1MThe role, mechanism and therapeutic potential of TET1 in MDSR56DK120282 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, JIANJUN · 2018 to 2018
$100kNIDDK NIH HHS R56 DK120282
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.